By combining complementary peptides, we can create a multi-pronged approach to wellness that a single peptide cant achieve alone
The GLP-1RAs, particularly semaglutide, are now used on a global scale for diabetes and obesity, and emerging pharmacovigilance reports suggest that some patients may experience oral and salivary symptoms during therapy, including xerostomia, dysgeusia, oral hypoesthesia, and throat discomfort [1]
PlexusDx Precision Peptide Genetic Test identifies your GLP1R, FTO, MC4R, and GIPR variants, revealing whether you are a fast responder, slow responder, or sensitive to dose escalation
Results develop gradually, and your healthcare provider will guide and monitor your progress to ensure the best outcomes
Its FDA approval provides regulatory advantage and its targeted mechanism provides unique research opportunities
At Healthon, we have conducted extensive due diligence and partnered exclusively with reputable, fully compliant, US-based compounding pharmacies